share_log

Verona Pharma To Present Additional Analyses Of Phase 3 ENHANCE Studies In COPD At ATS 2024

Benzinga ·  May 2 03:44

PDUFA Target Action Date of June 26, 2024
Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment